The Predictive Value of Pre-therapeutic Serum Gamma-glutamyl transferase in Efficacy and Adverse Reactions to Neoadjuvant Chemotherapy among Breast Cancer Patients.
Conclusion: Pre-therapeutic serum GGT level is an independent and novel biomarker for predicting the efficiency, prognosis, and adverse reactions to NAC in breast cancer patients. Patients with low pre-therapeutic serum GGT levels are more likely to have higher pCR rates, better RFS and DFS, and higher hematologic toxicity.
Trial Registration: ClinicalTrials.gov Identifier: NCT02199418, NCT02221999.
PMID: 33154826 [PubMed]
Source: Journal of Breast Cancer - Category: Cancer & Oncology Tags: J Breast Cancer Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Hematology | Hormones | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Study | Toxicology